Home Supplemental Immune Globulins in Sepsis
Article
Licensed
Unlicensed Requires Authentication

Supplemental Immune Globulins in Sepsis

  • Karl Werdan
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 37 Issue 3

Abstract

Intravenous immune globulins are widely used as supplemental treatment of sepsis, septic shock and systemic inflammation in the critically ill, although this indication has at best been validated in part. Likely beneficial mechanisms of action may include the improvement of serum bactericidal activity due to neutralizing and opsonizing immunoglobulin (Ig)G- and IgM-antibodies, as well as stimulation of phagocytosis and neutralization of bacterial endo- and exotoxins; another attractive mode of action may represent immune globulin-mediated modification and specific suppression of proinflammatory cytokine release from endotoxin- and superantigen-activated blood cells. For the “entire group of patients with sepsis and septic shock” a reduction in mortality by intravenous immune globulin could not be documented; however, in the score-based immunoglobulin in sepsis (SBITS)-study with 653 patients included, a moderate improvement in sepsis morbidity and multiple organ dysfunction syndrome was demonstrated. In defined sepsis subgroups, a reduction in mortality by intravenous immune globulin has been seen in individual small, not yet confirmed trials. Finally, the incidence of some severe infections in well characterized “patients at risk” and “operations at risk” is reduced by intravenous immune globulin prophylaxis. Thus, intravenous immune globulin is not a “magic bullet” of sepsis treatment, but it may reduce morbidity and thereby represent a useful piece of stone in the therapeutic mosaic of sepsis treatment.

:
Published Online: 2005-06-01
Published in Print: 1999-03-01

Copyright (c)1999 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. IFCC/Beckman European Conference 1998 Frontiers in Molecular Basis of Disease: Inflammatory Diseases
  2. Frontiers in Molecular Basis of Disease: Inflammatory Diseases
  3. Mechanisms of Antigen Presentation
  4. How to Extinguish Lymphocyte Activation, Immunotyrosine-Based Inhibition Motif (ITIM)-Bearing Molecules a Solution?
  5. Association between Reduced Human Leukocyte Antigen (HLA)-DR Expression on Blood Monocytes and Increased Plasma Level of Interleukin-10 in Patients with Severe Burns
  6. Immunostimulatory CpG Motifs Trigger a T Helper-1 Immune Response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 Envelope Proteins
  7. Activation and Regulation of NFκB during Acute Inflammation
  8. CD 14++ Monocytes, CD14+/CD16+ Subset and Soluble CD14 as Biological Markers of Inflammatory Systemic Diseases and Monitoring Immuno-suppressive Therapy
  9. A Potential Role of an Intracellular Signaling Defect in Neutrophil Functional Abnormalities and Promotion of Tissue Damage in Patients with Localized Juvenile Periodontitis
  10. Polymorphonuclear Oxidative Burst after Helicobacter pylori Water Extract Stimulation Is not Influenced by the Cytotoxic Genotype but Indicates Infection and Gastritis Grade
  11. Flow Cytometry of Cerebrospinal Fluid (CSF) Lymphocytes: Alterations of Blood/CSF Ratios of Lymphocyte Subsets in Inflammation Disorders of Human Central Nervous System (CNS)
  12. Effects of Oxidized Low Density Lipoprotein, Lipid Mediators and Statins on Vascular Cell Interactions
  13. Mycophenolic Acid Influences T Helper 2 (Th2) Cytokine Induced Expression of Intercellular Cell Adhesion Molecule -1 (ICAM-1) on Human Endothelial Cells
  14. Alterations of Endothelial Nucleotide Levels by Mycophenolic Acid Result in Changes of Membrane Glycosylation and E-Selectin Expression
  15. C-Reactive Protein: Structural Biology and Host Defense Function
  16. A Novel Acute-Phase Marker: Lipopolysaccharide Binding Protein (LBP)
  17. Detection of Acute Phase Response and Infection. The Role of Procalcitonin and C-Reactive Protein
  18. Lactoferrin: A Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Process
  19. Annexin V and Phospholipid Metabolism
  20. Regulation of Leukocyte Trafficking by Lipoxins
  21. Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators
  22. Differentiation and Assessment of Cell Death
  23. Depending on Their Concentration Oxidized Low Density Lipoproteins Stimulate Extracellular Matrix Synthesis or Induce Apoptosis in Human Coronary Artery Smooth Muscle Cells
  24. Apheresis of Plasma Compounds as a Therapeutic Principle in Severe Sepsis and Multiorgan Dysfunction Syndrome
  25. Supportive Therapy of the Sepsis Syndrome
  26. Supplemental Immune Globulins in Sepsis
  27. Polymorphonuclear Granulocyte Stimulation by Cellulose-Based Hemodialysis Membranes
  28. Reduction of Circulating Cholesterol and Apolipoprotein Levels during Sepsis
  29. Outcome Prediction by Traditional and New Markers of Inflammation in Patients with Sepsis
  30. Isolation of Highly Enriched Human Monocytes from Ten ml Samples of Heparinised Whole Blood
  31. Endotoxin Adsorbant Based on Immobilized Human Serum Albumin
Downloaded on 9.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.1999.057/pdf
Scroll to top button